Pexacerfont

DB12572InvestigationalSmall molecule

Pexacerfont has been investigated for the treatment of Alcoholism, Anxiety Disorder, Alcohol Dependence, and Alcohol-Related Disorders.

Mechanism: Pharmacologically active on Corticotropin-releasing hormone receptor 1
Curator reviewed
Formula / weight: C₁₈H₂₄N₆O · 340.431 g/mol (avg)
Code names: BMS-562086

Resolves to

Compound

Structure

InChIKeyLBWQSAZEYIZZCE-SNVBAGLBSA-NSMILESCC[C@@H](C)NC1=NC(C)=NC2=C(C(C)=NN12)C1=CC=C(OC)N=C1C

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pexacerfont, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.